211 related articles for article (PubMed ID: 16600541)
1. Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant.
Takatsuka S; Morita T; Koguchi A; Horikiri Y; Yamahara H; Yoshino H
Int J Pharm; 2006 Jun; 316(1-2):124-30. PubMed ID: 16600541
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant.
Takatsuka S; Kitazawa T; Morita T; Horikiri Y; Yoshino H
Eur J Pharm Biopharm; 2006 Jan; 62(1):52-8. PubMed ID: 16289777
[TBL] [Abstract][Full Text] [Related]
3. Influence of various combinations of mucolytic agent and non-ionic surfactant on intestinal absorption of poorly absorbed hydrophilic compounds.
Takatsuka S; Morita T; Horikiri Y; Yamahara H; Saji H
Int J Pharm; 2008 Feb; 349(1-2):94-100. PubMed ID: 17869034
[TBL] [Abstract][Full Text] [Related]
4. Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant.
Takatsuka S; Morita T; Horikiri Y; Yamahara H; Saji H
Int J Pharm; 2007 Jun; 338(1-2):87-93. PubMed ID: 17317052
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2006 Jan; 110(2):347-352. PubMed ID: 16274829
[TBL] [Abstract][Full Text] [Related]
6. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2006 Oct; 115(2):183-8. PubMed ID: 16989920
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
8. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.
Song KH; Chung SJ; Shim CK
J Control Release; 2005 Sep; 106(3):298-308. PubMed ID: 15979756
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride.
du Plessis LH; Lubbe J; Strauss T; Kotzé AF
Int J Pharm; 2010 Jan; 385(1-2):181-6. PubMed ID: 19854253
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).
Sinko PJ; Lee YH; Makhey V; Leesman GD; Sutyak JP; Yu H; Perry B; Smith CL; Hu P; Wagner EJ; Falzone LM; McWhorter LT; Gilligan JP; Stern W
Pharm Res; 1999 Apr; 16(4):527-33. PubMed ID: 10227707
[TBL] [Abstract][Full Text] [Related]
11. Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs.
Lee YH; Perry BA; Sutyak JP; Stern W; Sinko PJ
Pharm Res; 2000 Mar; 17(3):284-90. PubMed ID: 10801216
[TBL] [Abstract][Full Text] [Related]
12. Enhanced transbuccal salmon calcitonin (sCT) delivery: effect of chemical enhancers and electrical assistance on in vitro sCT buccal permeation.
Oh DH; Chun KH; Jeon SO; Kang JW; Lee S
Eur J Pharm Biopharm; 2011 Oct; 79(2):357-63. PubMed ID: 21683790
[TBL] [Abstract][Full Text] [Related]
13. Mucoadhesive intestinal devices for oral delivery of salmon calcitonin.
Gupta V; Hwang BH; Lee J; Anselmo AC; Doshi N; Mitragotri S
J Control Release; 2013 Dec; 172(3):753-62. PubMed ID: 24035976
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin.
Aguirre TA; Rosa M; Coulter IS; Brayden DJ
Eur J Pharm Sci; 2015 Nov; 79():102-11. PubMed ID: 26349051
[TBL] [Abstract][Full Text] [Related]
15. Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
Aguirre TAS; Aversa V; Rosa M; Guterres SS; Pohlmann AR; Coulter I; Brayden DJ
J Control Release; 2016 Sep; 238():242-252. PubMed ID: 27480451
[TBL] [Abstract][Full Text] [Related]
16. Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine.
Sakuma S; Sudo R; Suzuki N; Kikuchi H; Akashi M; Ishida Y; Hayashi M
J Control Release; 2002 Jun; 81(3):281-90. PubMed ID: 12044567
[TBL] [Abstract][Full Text] [Related]
17. Absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs including peptide and protein drugs in rats.
Alama T; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Int J Pharm; 2016 Feb; 499(1-2):58-66. PubMed ID: 26707414
[TBL] [Abstract][Full Text] [Related]
18. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa.
Makhlof A; Werle M; Tozuka Y; Takeuchi H
J Control Release; 2011 Jan; 149(1):81-8. PubMed ID: 20138935
[TBL] [Abstract][Full Text] [Related]
19. Loss of the intestinal mucus layer in the normal rat causes gut injury but not toxic mesenteric lymph nor lung injury.
Sharpe SM; Qin X; Lu Q; Feketeova E; Palange DC; Dong W; Sheth SU; Lee MA; Reino D; Xu DZ; Deitch EA
Shock; 2010 Nov; 34(5):475-81. PubMed ID: 20220565
[TBL] [Abstract][Full Text] [Related]
20. Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer.
Petersen SB; Nielsen LG; Rahbek UL; Guldbrandt M; Brayden DJ
Eur J Pharm Sci; 2013 Mar; 48(4-5):726-34. PubMed ID: 23354154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
